118 related articles for article (PubMed ID: 38331350)
1. TP53
Su Y; Zhao J; Fu H; Liu Z; Du P; Zheng J; Wu J; Zhang J
Biochem Pharmacol; 2024 Mar; 221():116047. PubMed ID: 38331350
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.
Kim JY; Jung J; Kim KM; Lee J; Im YH
Cancer Med; 2023 Jun; 12(11):12438-12451. PubMed ID: 37081749
[TBL] [Abstract][Full Text] [Related]
3. Triptolide promotes degradation of the unfolded gain-of-function Tp53
Zhou J; Luo J; Li P; Zhou Y; Li P; Wang F; Mallio CA; Rossi G; Jalal AH; Filipovic N; Tian Z; Zhao X
Transl Lung Cancer Res; 2022 May; 11(5):802-816. PubMed ID: 35693277
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53
Polireddy K; Singh K; Pruski M; Jones NC; Manisundaram NV; Ponnela P; Ouellette M; Van Buren G; Younes M; Bynon JS; Dar WA; Bailey JM
Cancer Lett; 2019 Jul; 453():122-130. PubMed ID: 30946870
[TBL] [Abstract][Full Text] [Related]
5. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
6. Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophages.
Behring M; Vazquez AI; Cui X; Irvin MR; Ojesina AI; Agarwal S; Manne U; Shrestha S
Mol Genet Genomic Med; 2019 Dec; 7(12):e1001. PubMed ID: 31637877
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of CD117 expression and
Luo Y; Huang W; Zhang H; Liu G
Oncol Lett; 2018 May; 15(5):6161-6170. PubMed ID: 29616097
[TBL] [Abstract][Full Text] [Related]
8. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
9. DNAJA1 promotes proliferation and metastasis of breast cancer by activating mutant P53/NF-κB pathway.
Wu J; Yang Q; Zhu Y; Xia T; Yi L; Wang J; Ren X
Pathol Res Pract; 2023 Dec; 252():154921. PubMed ID: 37977037
[TBL] [Abstract][Full Text] [Related]
10. Tanshinone IIA promotes apoptosis by downregulating BCL2 and upregulating TP53 in triple-negative breast cancer.
Liu J; Zhang C; Liu S; Wang X; Wu X; Hao J
Naunyn Schmiedebergs Arch Pharmacol; 2023 Feb; 396(2):365-374. PubMed ID: 36374307
[TBL] [Abstract][Full Text] [Related]
11. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.
Ozcelik H; Pinnaduwage D; Bull SB; Andrulis IL
Breast Cancer Res Treat; 2007 Nov; 105(3):255-65. PubMed ID: 17221157
[TBL] [Abstract][Full Text] [Related]
12. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
[TBL] [Abstract][Full Text] [Related]
13. Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.
Yi Z; Ma F; Rong G; Guan Y; Li C; Xu B
Cancer Commun (Lond); 2020 Jun; 40(6):260-269. PubMed ID: 32436611
[TBL] [Abstract][Full Text] [Related]
14. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
15. Different TP53 mutations are associated with specific chromosomal rearrangements, telomere length changes, and remodeling of the nuclear architecture of telomeres.
Samassekou O; Bastien N; Lichtensztejn D; Yan J; Mai S; Drouin R
Genes Chromosomes Cancer; 2014 Nov; 53(11):934-50. PubMed ID: 25059482
[TBL] [Abstract][Full Text] [Related]
16. The Function of the Mutant p53-R175H in Cancer.
Chiang YT; Chien YC; Lin YH; Wu HH; Lee DF; Yu YL
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439241
[TBL] [Abstract][Full Text] [Related]
17. Distinct TP53 Mutation Types Exhibit Increased Sensitivity to Ferroptosis Independently of Changes in Iron Regulatory Protein Activity.
Thompson LR; Oliveira TG; Hermann ER; Chowanadisai W; Clarke SL; Montgomery MR
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942535
[TBL] [Abstract][Full Text] [Related]
18. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.
Li X; Chen X; Wen L; Wang Y; Chen B; Xue Y; Guo L; Liao N
Thorac Cancer; 2020 Jul; 11(7):1861-1868. PubMed ID: 32412177
[TBL] [Abstract][Full Text] [Related]
19.
Huszno J; Grzybowska E
Oncol Lett; 2018 Jul; 16(1):34-40. PubMed ID: 29928384
[TBL] [Abstract][Full Text] [Related]
20. The targeted next-generation sequence revealed SMAD4, AKT1, and TP53 mutations from circulating cell-free DNA of breast cancer and its effect on protein structure - A computational approach.
Balasundaram A; Kumar S U; D TK; Anil Dedge A; R G; K SS; R S; C GPD
J Biomol Struct Dyn; 2023; 41(24):15584-15597. PubMed ID: 37011004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
